← All trials
NCT03213405
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2017
- Primary completion
- May 20, 2018
- Completion date
- May 20, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pontificia Universidad Catolica de ChileLead sponsor
- Comisión Nacional de Investigación Científica y TecnológicaCollaborator
- Pontificia Universidad Catolica de ChileStudy director
- Government of ChileCollaborator
- Millennium Institute on Immunology and Immunotherapy, ChileCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.